Risk Heterogeneity of Liver‐Related Events and Extrahepatic Outcomes Across MASLD Phenotypes and Risk Stratification by Liver Fibrosis

<b>Background:</b> Metabolic dysfunction-associated steatotic liver disease (MASLD) has been newly proposed to characterize fatty liver disease. We aim to investigate the associations of different phenotypes of MASLD and related steatotic liver disease (SLD) with the risk of liver-related and extrahepatic outcomes. <b>Methods:</b> Among 368,886 United Kingdom's Biobank participants, those with MASLD and related SLD were categorized into pure MASLD, MASLD with increased alcohol intake (MetALD), MASLD with alcohol-related liver disease (ALD), and MASLD with other etiology. The primary outcome was liver-related events (LREs). <b>Results:</b> During a median follow-up of 13.7 years, 2095 participants developed LREs. The adjusted HRs (95% CIs) of LREs for pure MASLD, MetALD, MASLD with ALD, and MASLD with other etiology were 2.46 (2.21, 2.73), 2.77 (2.39, 3.21), 8.73 (7.59, 10.1), and 26.5 (17.1, 41.0), respectively. Participants with MetALD, MASLD with ALD, and MASLD with other etiology showed a considerably higher risk of liver-related outcomes but a modestly higher risk of extrahepatic cancer compared to those with pure MASLD. A remarkably higher risk of LREs was observed in participants with a fibrosis-4 > 2.67. <b>Conclusion:</b> MASLD and related SLD are associated with increased risks of LREs and extrahepatic outcomes, with heterogeneous risks across different phenotypes and significant risk stratification by liver fibrosis severity.

Authors

Institutions

Publication Details

Journal
International Journal of Endocrinology
Published
2025-01-01
DOI
https://doi.org/10.1155/ije/1262001
Citations
2
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
2.71

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Risk Heterogeneity of Liver‐Related Events and Extrahepatic Outcomes Across MASLD Phenotypes and Risk Stratification by Liver Fibrosis

Xinlin Zhang, Songjiang Yin, Xue Bao, Xiaowen Zhang et al.
2 citations
International Journal of Endocrinology
Liver Disease Diagnosis and Treatment
2.71
article

Risk Heterogeneity of Liver‐Related Events and Extrahepatic Outcomes Across MASLD Phenotypes and Risk Stratification by Liver Fibrosis

Xinlin Zhang, Songjiang Yin, Xue Bao, Xiaowen Zhang, Yu Wang, Dahui Xu
article en
2 citations

Abstract

<b>Background:</b> Metabolic dysfunction-associated steatotic liver disease (MASLD) has been newly proposed to characterize fatty liver disease. We aim to investigate the associations of different phenotypes of MASLD and related steatotic liver disease (SLD) with the risk of liver-related and extrahepatic outcomes. <b>Methods:</b> Among 368,886 United Kingdom's Biobank participants, those with MASLD and related SLD were categorized into pure MASLD, MASLD with increased alcohol intake (MetALD), MASLD with alcohol-related liver disease (ALD), and MASLD with other etiology. The primary outcome was liver-related events (LREs). <b>Results:</b> During a median follow-up of 13.7 years, 2095 participants developed LREs. The adjusted HRs (95% CIs) of LREs for pure MASLD, MetALD, MASLD with ALD, and MASLD with other etiology were 2.46 (2.21, 2.73), 2.77 (2.39, 3.21), 8.73 (7.59, 10.1), and 26.5 (17.1, 41.0), respectively. Participants with MetALD, MASLD with ALD, and MASLD with other etiology showed a considerably higher risk of liver-related outcomes but a modestly higher risk of extrahepatic cancer compared to those with pure MASLD. A remarkably higher risk of LREs was observed in participants with a fibrosis-4 > 2.67. <b>Conclusion:</b> MASLD and related SLD are associated with increased risks of LREs and extrahepatic outcomes, with heterogeneous risks across different phenotypes and significant risk stratification by liver fibrosis severity.

International Journal of EndocrinologyVol. 2025(1)
Nanjing University of Chinese Medicine (CN), Tianjin Nankai Hospital (CN), Nanjing Drum Tower Hospital (CN)
National Natural Science Foundation of China, Nanjing University
Openalex Percentile: Top 10%
Liver Disease Diagnosis and Treatment
2.71
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.